VeraBank N.A. Purchases New Stake in Zimmer Biomet Holdings, Inc. $ZBH

VeraBank N.A. acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 2nd quarter, Holdings Channel.com reports. The firm acquired 3,993 shares of the medical equipment provider’s stock, valued at approximately $364,000.

Several other institutional investors also recently made changes to their positions in the stock. Accent Capital Management LLC purchased a new position in shares of Zimmer Biomet in the 1st quarter valued at about $35,000. Cullen Frost Bankers Inc. grew its position in Zimmer Biomet by 1,452.4% during the first quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 305 shares during the period. Hilltop National Bank purchased a new position in Zimmer Biomet in the second quarter valued at about $42,000. True Wealth Design LLC boosted its stake in shares of Zimmer Biomet by 875.0% during the 2nd quarter. True Wealth Design LLC now owns 468 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 420 shares in the last quarter. Finally, Zions Bancorporation National Association UT acquired a new stake in shares of Zimmer Biomet in the 1st quarter worth approximately $48,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $88.52 on Wednesday. The stock has a market capitalization of $17.54 billion, a P/E ratio of 21.54, a P/E/G ratio of 2.29 and a beta of 0.67. Zimmer Biomet Holdings, Inc. has a 12-month low of $85.33 and a 12-month high of $114.72. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The firm’s 50-day moving average is $99.46 and its two-hundred day moving average is $97.29.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2 billion for the quarter, compared to the consensus estimate of $2.01 billion. During the same quarter in the prior year, the firm posted $1.74 earnings per share. The company’s quarterly revenue was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th were issued a dividend of $0.24 per share. The ex-dividend date was Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is 23.76%.

Wall Street Analysts Forecast Growth

ZBH has been the topic of several research reports. Redburn Partners set a $130.00 target price on Zimmer Biomet in a report on Thursday, September 18th. Roth Capital reissued a “buy” rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. JPMorgan Chase & Co. restated a “neutral” rating and set a $100.00 target price (down from $115.00) on shares of Zimmer Biomet in a report on Thursday, November 6th. Evercore ISI reduced their price target on shares of Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a report on Tuesday, October 7th. Finally, Wall Street Zen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $109.00.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares in the company, valued at approximately $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.70% of the stock is currently owned by corporate insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.